Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, Arrowhead Pharmaceuticals Inc’s stock clocked out at $19.50, down -1.47% from its previous closing price of $19.79. In other words, the price has decreased by -$1.47 from its previous closing price. On the day, 1.46 million shares were traded. ARWR stock price reached its highest trading level at $20.3 during the session, while it also had its lowest trading level at $19.155.
Ratios:
To gain a deeper understanding of ARWR’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.74 and its Current Ratio is at 6.74. In the meantime, Its Debt-to-Equity ratio is 4.59 whereas as Long-Term Debt/Eq ratio is at 4.56.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on June 05, 2024, initiated with a Neutral rating and assigned the stock a target price of $31.
On December 04, 2023, BofA Securities started tracking the stock assigning a Buy rating and target price of $29.
On September 19, 2023, Citigroup started tracking the stock assigning a Neutral rating and target price of $33.Citigroup initiated its Neutral rating on September 19, 2023, with a $33 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 02 ’25 when Anzalone Christopher Richard sold 11,520 shares for $19.05 per share. The transaction valued at 219,456 led to the insider holds 3,764,252 shares of the business.
Myszkowski Kenneth Allen bought 5,817 shares of ARWR for $115,318 on Jan 06 ’25. On Jan 06 ’25, another insider, Myszkowski Kenneth Allen, who serves as the Officer of the company, bought 9,255 shares for $19.82 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARWR now has a Market Capitalization of 2462557440 and an Enterprise Value of 2644916480. For the stock, the TTM Price-to-Sale (P/S) ratio is 688.38 while its Price-to-Book (P/B) ratio in mrq is 13.08. Its current Enterprise Value per Revenue stands at 134.615 whereas that against EBITDA is -4.992.
Stock Price History:
The Beta on a monthly basis for ARWR is 0.95, which has changed by -0.4801681 over the last 52 weeks, in comparison to a change of 0.24933672 over the same period for the S&P500. Over the past 52 weeks, ARWR has reached a high of $39.83, while it has fallen to a 52-week low of $17.05. The 50-Day Moving Average of the stock is -6.93%, while the 200-Day Moving Average is calculated to be -16.23%.
Shares Statistics:
It appears that ARWR traded 1.44M shares on average per day over the past three months and 1480590 shares per day over the past ten days. A total of 124.38M shares are outstanding, with a floating share count of 116.02M. Insiders hold about 6.76% of the company’s shares, while institutions hold 76.65% stake in the company. Shares short for ARWR as of 1731628800 were 9445166 with a Short Ratio of 6.81, compared to 1728950400 on 9334910. Therefore, it implies a Short% of Shares Outstanding of 9445166 and a Short% of Float of 8.9099996.
